glp-1 and gip receptor agonist New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity Overweight Free Comparison Chart: GLP-1 and

No pharmacotherapy is approved for the treatment of NAFLD and, currently, the cornerstone treatment is lifestyle modifications focusing on bodyweight loss, notoriously difficult to obtain and even more difficult to maintain

Su Y, Liu N, Zhang Z, Li H, Ma J, Yuan Y, et al

Kostadinova, Jan L

At 30 min (for pERK1/2 staining) or 90 min (for c-Fos staining) after injection, mice were transcardially perfused with phosphate buffer including 4% paraformaldehyde and 0.2% picric acid under anesthesia

How might this impact on clinical practice in the foreseeable future

American Diabetes Association Professional Practice Committee, 2022)